The World Health Organization (WHO) has issued a grim pronouncement: one in six laboratory-confirmed bacterial infections around the world is now resistant to at least one first-line antibiotic.
This assessment, drawn from data across 104 countries covering about 70% of the global population, marks a turning point in global health surveillance. The highest rates of resistance are reported in Southeast Asia and the Eastern Mediterranean, with approximately one in three infections showing resistance in those regions.
Urinary tract and bloodstream infections are especially affected, with severe implications for patient outcomes and healthcare systems. The WHO estimates that in 2021 alone, antimicrobial resistance (AMR) contributed to 4.7 million deaths, including over 1.14 million directly due to resistant infections.
The WHO warns that the pipeline for new antibiotics and diagnostics is stagnating, aggravated by cuts in public health funding globally. Persistent underinvestment threatens to render the world unprepared for the next generation of drug-resistant “superbugs.”
For Bangladesh, Nepal, Bhutan and India, the crisis is especially relevant—these countries already bear heavy burdens of infectious disease. The report strengthens calls for increased surveillance, antimicrobial stewardship, and equitable access to new treatments.
